Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Bristol Myers Squibb’s Eliquis is set to lose patent protection in 2028, which would likely trigger a sharp revenue decline as generics enter. The article argues BMY is working to offset the “patent cliff” with new drugs (e.g., Camzyos, Opdualag, Breyanzi, Reblozyl) and a deep pipeline, though it notes the balance of success needed. It also flags merger chatter with AstraZeneca as unlikely and frames the stock as reasonable but not a short-term buy, with the dividend cited at ~3.7%.

Analysis

The market mechanism here is less about 2028 earnings and more about the discount rate applied to BMY’s terminal growth. A well-telegraphed patent cliff usually compresses the multiple long before cash flow actually rolls over, so the stock can remain range-bound even if the next 12 months look stable. The key question is whether new launches can scale fast enough to keep the revenue base from stepping down in 2028-29; if not, the dividend may support the shares but won’t stop P/E erosion.

Second-order winners are generic small-molecule manufacturers and payors, but the bigger tradeable effect is on BMY’s competitive positioning versus large-cap pharma peers with cleaner growth runways. If the market keeps assigning takeover probability to BMY, that optionality is a hidden prop in the stock; if deal chatter fades, the equity loses a speculative floor without any offset in near-term fundamentals. AZN is not a likely acquirer in our base case, so the rumor premium is more likely to mean-revert than to convert into a bid.

Catalyst timing matters: the next 1-3 months are about pipeline readouts and launch-rate data, not the 2028 cliff itself; the 6-18 month story is whether management can prove replacement revenue before the market starts modeling the gap into consensus. The contrarian view is that the crowd may be too focused on the expiration date and underweight the fact that BMY is already producing offsets; the stock is not obviously cheap, but neither is the cliff fully punitive at current valuation. What would falsify the bull case is any evidence that new product growth stalls for two straight quarters or that management guides to a materially steeper post-2028 revenue decline than implied today.

Key Decisions for Investors

• Stay underweight BMY versus XLV on a 3-6 month horizon until launch growth is clearly offsetting legacy erosion; the risk/reward favors waiting for proof rather than paying for a recovery story.
• Use any rumor-driven pop in BMY to trim or hedge rather than chase; if the stock re-rates without a corresponding raise in long-term guidance, fade the move with a 1-3 month put spread.
• If M&A chatter resurfaces, express it as a relative-value trade: short BMY / long AZN, because the acquisition optionality is the weaker leg and BMY carries the more obvious terminal growth overhang.
• Treat the next earnings cycle as the real catalyst watchpoint: if BMY can print above-consensus launch uptake for Camzyos/Opdualag/Breyanzi and hold guidance, cover shorts; if not, the multiple can leak lower even before 2028.